Antiproliferative effects of curcumin analog L49H37 in pancreatic stellate cells: A comparative study

Annals of Gastroenterology

Volumn 28, Issue 3, 2015, Pages 389-396

  Gundewar, Chinmay ^a   Ansari, Daniel ^a,b   Tang, Longguang ^c   Wang, Yi ^c   Liang, Guang ^c   Rosendahl, Ann H ^a,b   Saleem, Moin A ^d   Andersson, Roland ^a,b  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c WENZHOU MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Cleaved PARP; P21^{WAF1 Cip1< sup>; Pancreatic cancer; Stroma}

Indexed keywords

1 METHYL 3,5 BIS(3,4,5 TRIMETHOXYBENZYLIDENE)PIPERIDIN 4 ONE; ANTINEOPLASTIC AGENT; CURCUMIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN P21; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE G0 PHASE; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOWN REGULATION; DRUG POTENCY; DRUG SYNTHESIS; ENZYME PHOSPHORYLATION; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VITRO STUDY; PANCREAS CANCER; PANCREATIC STELLATE CELL; PROTEIN CLEAVAGE; SIGNAL TRANSDUCTION;

EID: 84931376925     PISSN: 11087471     EISSN: 17927463     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.
2. Korc M. Pancreatic cancer-associated stroma production. Am J Surg 2007;194:s84-s86.
3. Hidalgo M. Pancreatic cancer. N Engl J Med 2010;362:1605-1617.
4. Welsch T, Kleeff J, Friess H. Molecular pathogenesis of pancreatic cancer: advances and challenges. Curr Mol Med 2007;7:504-521.
5. Apte MV, Park S, Phillips PA, et al. Desmoplastic reaction in pancreatic cancer: role of pancreatic stellate cells. Pancreas 2004;29:179-187.
6. Duner S, Lopatko Lindman J, Ansari D, Gundewar C, Andersson R. Pancreatic cancer: the role of pancreatic stellate cells in tumor progression. Pancreatology 2010;10:673-681.
7. Tang D, Wang D, Yuan Z, et al. Persistent activation of pancreatic stellate cells creates a microenvironment favorable for the malignant behavior of pancreatic ductal adenocarcinoma. Int J Cancer 2013;132:993-1003.
8. Masamune A, Shimosegawa T. Signal transduction in pancreatic stellate cells. J Gastroenterol 2009;44:249-260.
9. Mitra A, Satelli A, Yan J, et al. IL-30 (IL27p28) attenuates liver fibrosis through inducing NKG2D-rae1 interaction between NKT and activated hepatic stellate cells in mice. Hepatology 2014;60:2027-2039.
10. Erkan M, Adler G, Apte MV, et al. StellaTUM: current consensus and discussion on pancreatic stellate cell research. Gut 2012;61:172-178.
11. Stan SD, Singh SV, Brand RE. Chemoprevention strategies for pancreatic cancer. Nat Rev Gastroenterol Hepatol 2010;7:347-56.
12. Hatcher H, Planalp R, Cho J, Torti FM, Torti SV. Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci 2008;65:1631-1652.
13. Sun L, Liu J, Lin SS, et al. Potent anti-angiogenic activity of B19--a mono-carbonyl analogue of curcumin. Chin J Nat Med 2014;12:8-14.
14. Masamune A, Suzuki N, Kikuta K, Satoh M, Satoh K, Shimosegawa T. Curcumin blocks activation of pancreatic stellate cells. J Cell Biochem 2006;97:1080-1093.
15. Shehzad A, Wahid F, Lee YS. Curcumin in cancer chemoprevention: molecular targets, pharmacokinetics, bioavailability, and clinical trials. Arch Pharm (Weinheim) 2010;343:489-499.
16. Rosendahl AH, Gundewar C, Said Hilmersson K, Ni L, Saleem MA, Andersson R. Conditionally immortalized human pancreatic stellate cell lines demonstrate enhanced proliferation and migration in response to IGF-I. Exp Cell Res 2015;330:300-310.
17. Anand P, Sundaram C, Jhurani S, Kunnumakkara AB, Aggarwal BB. Curcumin and cancer: an “old-age” disease with an “age-old” solution. Cancer Lett 2008;267:133-164.
18. Wilson JS, Pirola RC, Apte MV. Stars and stripes in pancreatic cancer: role of stellate cells and stroma in cancer progression. Front Physiol 2014;5:52.
19. Olive KP, Jacobetz MA, Davidson CJ, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009;324:1457-1461.
20. Rucki AA, Zheng L. Pancreatic cancer stroma: understanding biology leads to new therapeutic strategies. World J Gastroenterol 2014;20:2237-2246.
21. Su CC, Lin JG, Li TM, et al. Curcumin-induced apoptosis of human colon cancer colo 205 cells through the production of ROS, Ca2+ and the activation of caspase-3. Anticancer Res 2006;26:4379-489.
22. Tsai MS, Weng SH, Kuo YH, Chiu YF, Lin YW. Synergistic effect of curcumin and cisplatin via down-regulation of thymidine phosphorylase and excision repair cross-complementary 1 (ERCC1). Mol Pharmacol 2011;80:136-146.
23. Sun XD, Liu XE, Huang DS. Curcumin induces apoptosis of triple-negative breast cancer cells by inhibition of EGFR expression. Mol Med Rep 2012;6:1267-1270.
24. Smith MR, Gangireddy SR, Narala VR, et al. Curcumin inhibits fibrosis-related effects in IPF fibroblasts and in mice following bleomycin-induced lung injury. Am J Physiol Lung Cell Mol Physiol 2010;298:L616-L625.
25. Gupta SC, Patchva S, Aggarwal BB. Therapeutic roles of curcumin: lessons learned from clinical trials. Aaps j 2013;15:195-218.
26. Yallapu MM, Jaggi M, Chauhan SC. Curcumin nanoformulations: a future nanomedicine for cancer. Drug Discov Today 2012;17:71-80.
27. Vyas A, Dandawate P, Padhye S, Ahmad A, Sarkar F. Perspectives on new synthetic curcumin analogs and their potential anticancer properties. Curr Pharm Des 2013;19:2047-2069.